CJC-1295 (DAC): PRODUCT DESCRIPTION
CJC-1295 (DAC) is tretasubtitute peptide hormone which is an improved version of GRF 1-29 with DAC (Drug affinity complex). It is a synthetic hormone that imitates the functioning of GHRH (growth hormone-releasing hormone or growth hormone-releasing factor (GRF)), as such, it is a growth hormone secretagogue. CJC-1295 (DAC) has a longer half-life compared to GHRH (1-29) as a result of its enhanced pharmacokinetics. These improvements are achieved as a result of the DAC-complex which increases its binding affinity with GHRH receptors and hence protecting the hormone from enzymatic degradation which normally reduces its half-life. CJC-1295 (DAC) bioconjugates with serum albumin and as such its half-life is extended as well as its therapuetic window. CJC-1295 (DAC) establishes protective groups around the amino acids of GHRH which are vulnerable to enzymatic degradation. CJC-1295 (DAC) is made up of 30 amino acids and a molecular mass of 3647.28 while its molecular formula is C165H269N47O46. Its amino acid sequence is Sequence: …show more content…
The researchers were conducting research with an aim to develop means of increasing the effective half-life period of GHRH (growth hormone release hormone) and as such treat visceral fat deposits which are common in obese AIDS patients. Scientists believed that exogenously increasing the levels of gGH would lead to lipolysis (increased fat loss). The company commenced studies to evaluate CJC-1295 (DAC) as a research compound in 2000 and in 2006, it performed a clinical trial (two double-blind, placebo-controlled, randomized trials) to test the efficacy, effectiveness, and safety profile of CJC-1295 (DAC) in human subjects. Currently, both animal based and human based studies have shown CJC-1295 (DAC) to possess therapeutically effective and with acceptable safety
CJC-1295 (DAC) is tretasubtitute peptide hormone which is an improved version of GRF 1-29 with DAC (Drug affinity complex). It is a synthetic hormone that imitates the functioning of GHRH (growth hormone-releasing hormone or growth hormone-releasing factor (GRF)), as such, it is a growth hormone secretagogue. CJC-1295 (DAC) has a longer half-life compared to GHRH (1-29) as a result of its enhanced pharmacokinetics. These improvements are achieved as a result of the DAC-complex which increases its binding affinity with GHRH receptors and hence protecting the hormone from enzymatic degradation which normally reduces its half-life. CJC-1295 (DAC) bioconjugates with serum albumin and as such its half-life is extended as well as its therapuetic window. CJC-1295 (DAC) establishes protective groups around the amino acids of GHRH which are vulnerable to enzymatic degradation. CJC-1295 (DAC) is made up of 30 amino acids and a molecular mass of 3647.28 while its molecular formula is C165H269N47O46. Its amino acid sequence is Sequence: …show more content…
The researchers were conducting research with an aim to develop means of increasing the effective half-life period of GHRH (growth hormone release hormone) and as such treat visceral fat deposits which are common in obese AIDS patients. Scientists believed that exogenously increasing the levels of gGH would lead to lipolysis (increased fat loss). The company commenced studies to evaluate CJC-1295 (DAC) as a research compound in 2000 and in 2006, it performed a clinical trial (two double-blind, placebo-controlled, randomized trials) to test the efficacy, effectiveness, and safety profile of CJC-1295 (DAC) in human subjects. Currently, both animal based and human based studies have shown CJC-1295 (DAC) to possess therapeutically effective and with acceptable safety